Minimally important differences for interpreting the EORTC QLQ-C30 in patients with advanced colorectal cancer treated with chemotherapy
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Minimally important differences for interpreting the EORTC QLQ-C30 in patients with advanced colorectal cancer treated with chemotherapy. / Musoro, J. Z.; Sodergren, S. C.; Coens, C.; Pochesci, A.; Terada, M.; King, M. T.; Sprangers, M. A.G.; Grønvold, M.; Cocks, K.; Velikova, G.; Flechtner, H. H.; Bottomley, A.
I: Colorectal Disease, Bind 22, Nr. 12, 2020, s. 2278-2287.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Minimally important differences for interpreting the EORTC QLQ-C30 in patients with advanced colorectal cancer treated with chemotherapy
AU - Musoro, J. Z.
AU - Sodergren, S. C.
AU - Coens, C.
AU - Pochesci, A.
AU - Terada, M.
AU - King, M. T.
AU - Sprangers, M. A.G.
AU - Grønvold, M.
AU - Cocks, K.
AU - Velikova, G.
AU - Flechtner, H. H.
AU - Bottomley, A.
PY - 2020
Y1 - 2020
N2 - Aim: The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) assesses the health-related quality of life of patients in cancer trials. There are currently no minimally important difference (MID) guidelines for the EORTC QLQ-C30 for colorectal cancer (CRC). This study aims to estimate MIDs for the EORTC QLQ-C30 scales in patients with advanced CRC treated with chemotherapy and enrolled in clinical trials. Method: The data were obtained from three published EORTC trials that treated CRC patients using chemotherapy. Potential anchors were selected from clinical variables based on their correlation with EORTC QLQ-C30 scales. Anchor-based MIDs for within-group change and between-group change were estimated via the mean change method and linear regression, respectively, and summarized using weighted correlation. Distribution-based MIDs were also examined. Results: Anchor-based MIDs were determined for deterioration in 8 of the 14 EORTC QLQ-C30 scales and in 9 scales for improvement, and varied by scale, direction of change and anchor. MIDs for improvement (deterioration) ranged from 6 to 18 (−11 to −5) points for within-group change and 5 to 15 (−10 to −4) for between-group change. Summarized MIDs (in absolute values) per scale mostly ranged from 5 to 10 points. Conclusions: These findings have clinical relevance for the interpretation of treatment efficacy and the design of clinical trials by informing sample size requirements.
AB - Aim: The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) assesses the health-related quality of life of patients in cancer trials. There are currently no minimally important difference (MID) guidelines for the EORTC QLQ-C30 for colorectal cancer (CRC). This study aims to estimate MIDs for the EORTC QLQ-C30 scales in patients with advanced CRC treated with chemotherapy and enrolled in clinical trials. Method: The data were obtained from three published EORTC trials that treated CRC patients using chemotherapy. Potential anchors were selected from clinical variables based on their correlation with EORTC QLQ-C30 scales. Anchor-based MIDs for within-group change and between-group change were estimated via the mean change method and linear regression, respectively, and summarized using weighted correlation. Distribution-based MIDs were also examined. Results: Anchor-based MIDs were determined for deterioration in 8 of the 14 EORTC QLQ-C30 scales and in 9 scales for improvement, and varied by scale, direction of change and anchor. MIDs for improvement (deterioration) ranged from 6 to 18 (−11 to −5) points for within-group change and 5 to 15 (−10 to −4) for between-group change. Summarized MIDs (in absolute values) per scale mostly ranged from 5 to 10 points. Conclusions: These findings have clinical relevance for the interpretation of treatment efficacy and the design of clinical trials by informing sample size requirements.
KW - Advanced colorectal cancer
KW - clinical anchors
KW - EORTC QLQ-C30
KW - health-related quality of life (HRQOL)
KW - minimally important difference (MID)
U2 - 10.1111/codi.15295
DO - 10.1111/codi.15295
M3 - Journal article
C2 - 32767619
AN - SCOPUS:85089917201
VL - 22
SP - 2278
EP - 2287
JO - Colorectal Disease
JF - Colorectal Disease
SN - 1462-8910
IS - 12
ER -
ID: 248287456